NCT00193271View on ClinicalTrials.gov

Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions

Prostate Cancer

Interventions

DRUG

Docetaxel

DRUG

Estramustine

Trial Locations (1)

37023

Tennessee Oncology, PLLC, Nashville

Sponsors

Collaborators (1)

Aventis Pharmaceuticals

All Listed Sponsors

collaborator

Aventis Pharmaceuticals

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER